Dr Reddys launches Bortezomib for Injection 35 mg in US market

29 Jul 2022 , 01:32 AM

Dr Reddys Laboratories announced the launch of Bortezomib for Injection 35 mg the generic equivalent of Velcade bortezomib Injection in the US market approved by the US Food and Drug Administration USFDA The Velcade Brand and generic had US sales of approximately $12 billion MAT for the most recent twelve months ending in May 2022 according to IQVIA Health Dr Reddys Bortezomib for Injection is supplied in a 35 mg per 10 mL single-dose vial presentation for subcutaneous SQ or intravenous IV use